Please assess the completion status of the following clinical trial:

Trial Title: Oxybutynin Chloride in Managing Hot Flashes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* History of breast cancer, ductal breast carcinoma in situ (DCIS), or lobular carcinoma in situ (LCIS) (currently without evidence of malignant disease) OR a concern about taking estrogen for fear of breast cancer~* Bothersome hot flashes (defined by their occurrence of \>= 28 times per week and of sufficient severity to prompt the patient to seek therapeutic intervention)~* Presence of hot flashes for \> 30 days prior to study entry~* Ability to complete questionnaire(s) by themselves or with assistance~* Eastern Cooperative Oncology Group (ECOG) performance status (PS) = 0, 1~* Ability to provide informed written consent~* Life expectancy \>= 6 months~* Willing to work with the enrolling institution for follow-up (during the active monitoring phase of the study)~Exclusion Criteria:~* Any of the following current (=\< 4 weeks prior) or planned therapies:~  * Antineoplastic chemotherapy (anti-HER2 agents allowed)~ * Androgens~ * Estrogens (any delivery route)~ * Progestogens~ * Tamoxifen, raloxifene and aromatase inhibitors are allowed, but patient must have been on a constant dose for at least 28 days and must not be expected to stop the medication during the study period~ * Selective serotonin reuptake inhibitors (SSRIs)/serotonin?norepinephrine reuptake inhibitors (SNRIs), when being used for hot flash management or other indications such as depression, is allowed, assuming the dose will remain unchanged for the study duration~ * Gabapentin/pregabalin, when being used for hot flash management (use for other indications, such as pain, is allowed, assuming the dose will remain unchanged for the study duration)~ * Clonidine~ * Agents with known potent anticholinergic activity; agents with mild-moderate anticholinergic activity are allowed~* Prior use of oxybutynin during the period in which patient has had hot flashes~* Pregnant women~* Nursing women~* History of any of the following contraindications to oxybutynin:~  * Uncontrolled gastroesophageal reflux disease (GERD) despite appropriate therapy; if patient has history of GERD, but symptoms are well-controlled with medical treatment, patient is eligible~ * Ulcerative colitis~ * Narrow-angle glaucoma~ * Urinary retention~ * Hypersensitivity to oxybutynin or any other components of the product~ * Current uncontrolled hyperthyroidism~ * Coronary heart disease (angina or prior myocardial infarction)~ * Congestive heart failure~ * Symptomatic cardiac arrhythmias~ * Current uncontrolled hypertension~ * Myasthenia gravis~ * Dementia

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group I (low-dose oxybutynin chloride) (Type: EXPERIMENTAL): Patients receive lower dose oxybutynin chloride PO BID on days 8-49 in the absence of unacceptable toxicity.
- Group II (low-dose placebo) (Type: PLACEBO_COMPARATOR): Patients receive lower dose placebo PO BID on days 8-49 in the absence of unacceptable toxicity.
- Group III (high-dose oxybutynin chloride) (Type: EXPERIMENTAL): Patients receive lower dose oxybutynin chloride PO BID on days 8-14 and higher dose oxybutynin chloride on days 15-49 in the absence of unacceptable toxicity.
- Group IV (high-dose placebo) (Type: PLACEBO_COMPARATOR): Patients receive lower dose placebo PO BID on days 8-14 and higher dose placebo on days 15-49 in the absence of unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).